NCT02267226CompletedPhase 3
Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy and Safety of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Subjects With Congenital Fibrinogen Deficiency
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Octapharma
- Enrollment
- 25
- Locations
- 12
- Primary Endpoint
- Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in Treating the First Documented Bleeding Episode of Each Patient.
Study Overview
Brief Summary
The purpose of the study is to assess the efficacy and safety of Octafibrin for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiency.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 12 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Aged ≥12 years (only 18 and above in Russia)
- •Documented diagnosis of congenital fibrinogen deficiency, expected to require on-demand treatment for bleeding or surgical prophylaxis:
- •Fibrinogen deficiency manifested as afibrinogenaemia or severe hypofibrinogenaemia.
- •Historical plasma fibrinogen activity of <50 mg/dL or levels below the limit of detection of the local assay method.
- •Expected to have an acute bleeding episode (spontaneous or after trauma) or planning to undergo elective surgery.
- •Informed consent signed by the subject or legal guardian.
Exclusion Criteria
- •Life expectancy <6 months.
- •Bleeding disorder other than congenital fibrinogen deficiency, including dysfibrinogenaemia.
- •Prophylactic treatment with a fibrinogen concentrate.
- •Treatment with:
- •Any fibrinogen concentrate or other fibrinogen-containing blood product within 2 weeks prior to start of treatment for the bleeding episode or surgery.
- •Any coagulation-active drug (i.e., non-steroidal anti-inflammatory drugs, warfarin, coumarin derivatives, platelet aggregation inhibitors) within 1 week prior to start of treatment for the bleeding episode or surgery, or as a planned or expected medication during the time period from Day 1 until 24 hours (i.e., 1 day) after the last Octafibrin infusion.
- •Presence or history of:
- •Hypersensitivity to study medication.
- •Deep vein thrombosis or pulmonary embolism within 1 year prior to start of treatment for the bleeding episode or surgery.
- •Arterial thrombosis within 1 year prior to start of treatment for the bleeding episode or surgery
- •Hypersensitivity to human plasma proteins.
- •Oesophageal varicose bleeding.
- •End-stage liver disease (i.e., Child-Pugh score B or C).
- •Pregnant women within the first 20 weeks of gestation.
- •Currently breast-feeding.
- •Known positive HIV infection with a viral load >200 particles/μL or >400,000 copies/mL.
- •Polytrauma 1 year prior to start of treatment for the bleeding episode or surgery.
- •Diagnosis or suspicion of a neutralizing anti-fibrinogen inhibitor currently or any time in the past.
- •Acute or chronic medical condition which may, in the opinion of investigator, affect the conduct of the study, including
- •Subjects receiving immune-modulating drugs (other than anti-retroviral chemotherapy) such as alpha-interferon, prednisone (equivalent to >10 mg/day), or similar drugs at study start.
- •Subjects having evidence or a history (within the previous 12 months) of abuse of any licit or illicit drug substance.
- •Participation in another interventional clinical study currently or during the past 4 weeks.
Arms & Interventions
Octafibrin
Experimental
Intervention: Octafibrin (Drug)
Outcomes
Primary Outcomes
Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in Treating the First Documented Bleeding Episode of Each Patient.
Time Frame: 24 hours after last infusion for each bleeding episode
The first bleeding episode covers the time period from the first Octafibrin infusion until 24 hours (i.e., 1 day) after the last infusion. The investigator's overall clinical assessment of haemostatic efficacy for bleeding was based on a 4 point haemostatic efficacy scale. The final efficacy assessment of each patient was adjudicated by the Independent Data Monitoring \& Endpoint Adjudication Committee (IDMEAC).
Secondary Outcomes
- Maximum Clot Firmness (MCF) After Fibrinogen Infusion in Each Documented Bleeding Episode (BE), Measured in Frozen Plasma in a Central Laboratory.(Before first infusion and 1 hour after end of first and last infusion of each documented bleeding episode)
- Efficacy of Octafibrin in Preventing Bleeding During and After Surgery(First dose of Octafibrin administered prior to elective surgery to at least 3 post-operative days for minor and 7 post-operative days for major surgeries or last post-operative infusion, whichever comes last)
- Fibrinogen Plasma Level(Before (pre-infusion), 1 hour and 3 hours after the end of each subsequent infusion as well as at the time of the overall clinical assessment of haemostatic efficacy (i.e., 24 hours after the last infusion of each documented bleeding episode))
- Response as Indicated by Incremental in Vivo Recovery (IVR)(Pre-infusion and 1 and 3 hours post-infusion)
- Efficacy of Octafibrin for All Bleeding Episodes Collected in the Study(24 hours after last infusion for each bleeding episode)
Investigators
Study Sites (12)
Loading locations...
Similar Trials
Completed
Phase 3
Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen DeficiencyCongenital Fibrinogen DeficiencyNCT02408484Octapharma15
Completed
Phase 3
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminType 2 DiabetesNCT06045221Eli Lilly and Company1,698
Completed
Phase 3
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity DiseaseObesityNCT05931380Eli Lilly and Company238
Completed
Phase 3
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With MetforminType 2 DiabetesNCT06192108Eli Lilly and Company962
Completed
Phase 3
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesOverweightObesityType 2 DiabetesNCT05872620Eli Lilly and Company1,613